These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27588500)

  • 1. High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer.
    Cao ZG; Li JJ; Yao L; Huang YN; Liu YR; Hu X; Song CG; Shao ZM
    Oncotarget; 2016 Oct; 7(40):64900-64909. PubMed ID: 27588500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated miR-301a expression indicates a poor prognosis for breast cancer patients.
    Zheng JZ; Huang YN; Yao L; Liu YR; Liu S; Hu X; Liu ZB; Shao ZM
    Sci Rep; 2018 Feb; 8(1):2225. PubMed ID: 29396508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
    Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
    Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
    García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
    Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer.
    Jang MH; Kim HJ; Gwak JM; Chung YR; Park SY
    Hum Pathol; 2017 Oct; 68():69-78. PubMed ID: 28882698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
    Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
    Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.
    Zhang X; He Q; Sun L; Zhang Y; Qin S; Fan J; Wang J
    Dis Markers; 2019; 2019():6057280. PubMed ID: 31929841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
    Zeng Z; Chen X; Zhu D; Luo Z; Yang M
    Yonsei Med J; 2017 Jul; 58(4):697-702. PubMed ID: 28540980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
    Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
    Zavala V; Pérez-Moreno E; Tapia T; Camus M; Carvallo P
    Cancer Biomark; 2016; 16(1):99-107. PubMed ID: 26835710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miRNA-135b Contributes to
    Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
    Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
    Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
    Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of microRNAs in triple-negative breast cancer.
    Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
    Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
    Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
    Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer.
    Wong CK; Gromisch C; Ozturk S; Papageorgis P; Abdolmaleky HM; Reinhard BM; Thiagalingam A; Thiagalingam S
    Cancer Biol Ther; 2019; 20(8):1113-1120. PubMed ID: 30922194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.
    Xu YL; Yao R; Li J; Zhou YD; Mao F; Pan B; Sun Q
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1205-1213. PubMed ID: 28493031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.